Strategic Partnerships Position ContraFect as a partner for pharma and biotech firms targeting antibiotic-resistant infections. Their DLAs platform, including exebacase, shows traction with FDA Breakthrough Therapy designation and ongoing Phase 3 studies, making them a candidate for collaboration on combination therapies, manufacturing support, and access programs with larger biopharma players seeking novel modalities.

Clinical Expansion Leverage ongoing pivotal trials in MRSA bloodstream infections and expansion opportunities into prosthetic joint infections to identify potential investigator sites, CROs, and global markets where regulatory paths may be favorable or where unmet need is high, enabling out-licensing or co-development deals.

Funding Readiness Capitalize on substantial funding history and strategic grants (CARB-X, Cystic Fibrosis Foundation collaboration) to explore funding-driven partnerships, joint ventures, or milestone-based licensing deals with investors and health foundation programs seeking outcomes in antibiotic resistance.

Early Stage Commercials Target niche clinical indications where DLAs show rapid bactericidal activity and biofilm disruption, such as Staph aureus bacteremia and endocarditis, to build early access programs, hospital formularies, and payer discussions around value propositions of faster clearance and synergy with standard antibiotics.

Market Readiness Highlight the potential for global adoption through alliances with distributors and regional partners in markets facing high antimicrobial resistance, leveraging the Breakthrough Therapy designation and Phase 3 progression to accelerate market entry strategies and co-promotion opportunities.